Business Context and Reporting Period
This Form 8-K filing by Seres Therapeutics, Inc. (an emerging growth company) reports significant executive leadership changes effective January 14, 2019. The report was filed on January 15, 2019.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.
- Outgoing CEO Severance: Dr. Roger J. Pomerantz is entitled to severance payments and benefits as defined in his existing employment agreement for involuntary or constructive termination.
- Outgoing CEO Board Compensation: As Chairman and Director, Dr. Pomerantz will receive an annual retainer of $55,000 and an option to purchase 15,000 shares of common stock.
- New CEO Base Salary: Eric D. Shaff will receive an annual base salary of $540,000.
- New CEO Bonus: Annual target bonus opportunity of 55% of base salary.
- New CEO Equity: Expected grant of a stock option to purchase 275,000 shares, vesting over four years.
- Termination Benefits (New CEO): 12 months of base salary and medical coverage for termination without cause or resignation for good reason. In the event of a change in control, benefits increase to 18 months of salary and accelerated equity vesting.
Material Changes
The primary material change is the immediate resignation of Roger J. Pomerantz as President and Chief Executive Officer and the simultaneous appointment of Eric D. Shaff to those roles. Dr. Pomerantz remains on the Board as Chairman. Mr. Shaff, previously the Chief Financial Officer and Chief Operating Officer, has entered into an amended employment agreement superseding his prior terms.
Outlook, Risks, and Contingencies
The filing outlines specific contingencies regarding executive compensation tied to termination events and changes in control. Mr. Shaff's termination benefits are conditioned upon executing a general release of claims. Additionally, Mr. Shaff has agreed to a 12-month non-compete and non-solicitation period following termination. The filing notes that the Company believes Mr. Shaff is qualified for the Board due to his extensive executive-level experience in the biotechnology industry.
Investor Verification Checklist
- Review the full text of the Separation Agreement (Exhibit 10.1) to confirm the specific dollar amounts of Dr. Pomerantz's severance package.
- Review the Amended and Restated Employment Agreement (Exhibit 10.2) for detailed vesting schedules and change-in-control definitions for Mr. Shaff.
- Verify the impact of the leadership transition on the Company's ongoing clinical trials and operational strategy.
- Confirm the dilution impact of the 275,000 share option grant to Mr. Shaff and the 15,000 share option to Dr. Pomerantz.